Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Development of sulfonamide AKT PH domain inhibitors.

Ahad AM, Zuohe S, Du-Cuny L, Moses SA, Zhou LL, Zhang S, Powis G, Meuillet EJ, Mash EA.

Bioorg Med Chem. 2011 Mar 15;19(6):2046-54. doi: 10.1016/j.bmc.2011.01.049.

2.

Discovery of spirocyclic sulfonamides as potent Akt inhibitors with exquisite selectivity against PKA.

Xu R, Banka A, Blake JF, Mitchell IS, Wallace EM, Bencsik JR, Kallan NC, Spencer KL, Gloor SL, Martinson M, Risom T, Gross SD, Morales TH, Wu WI, Vigers GP, Brandhuber BJ, Skelton NJ.

Bioorg Med Chem Lett. 2011 Apr 15;21(8):2335-40. doi: 10.1016/j.bmcl.2011.02.098.

PMID:
21420856
3.

In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT.

Moses SA, Ali MA, Zuohe S, Du-Cuny L, Zhou LL, Lemos R, Ihle N, Skillman AG, Zhang S, Mash EA, Powis G, Meuillet EJ.

Cancer Res. 2009 Jun 15;69(12):5073-81. doi: 10.1158/0008-5472.CAN-08-3839.

4.

Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase B.

Collins I, Caldwell J, Fonseca T, Donald A, Bavetsias V, Hunter LJ, Garrett MD, Rowlands MG, Aherne GW, Davies TG, Berdini V, Woodhead SJ, Davis D, Seavers LC, Wyatt PG, Workman P, McDonald E.

Bioorg Med Chem. 2006 Feb 15;14(4):1255-73.

PMID:
16249095
5.
6.

Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.

Du-Cuny L, Song Z, Moses S, Powis G, Mash EA, Meuillet EJ, Zhang S.

Bioorg Med Chem. 2009 Oct 1;17(19):6983-92. doi: 10.1016/j.bmc.2009.08.022.

7.

Synthesis and structure-activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold.

Wurz RP, Liu L, Yang K, Nishimura N, Bo Y, Pettus LH, Caenepeel S, Freeman DJ, McCarter JD, Mullady EL, Miguel TS, Wang L, Zhang N, Andrews KL, Whittington DA, Jiang J, Subramanian R, Hughes PE, Norman MH.

Bioorg Med Chem Lett. 2012 Sep 1;22(17):5714-20. doi: 10.1016/j.bmcl.2012.06.078.

PMID:
22832322
8.

Discovery of a novel class of AKT pleckstrin homology domain inhibitors.

Mahadevan D, Powis G, Mash EA, George B, Gokhale VM, Zhang S, Shakalya K, Du-Cuny L, Berggren M, Ali MA, Jana U, Ihle N, Moses S, Franklin C, Narayan S, Shirahatti N, Meuillet EJ.

Mol Cancer Ther. 2008 Sep;7(9):2621-32. doi: 10.1158/1535-7163.MCT-07-2276.

9.

Discovery of 4-amino-2-(thio)phenol derivatives as novel protein kinase and angiogenesis inhibitors for the treatment of cancer: synthesis and biological evaluation. Part II.

Xu F, Zhang L, Jia Y, Wang X, Li X, Wen Q, Zhang Y, Xu W.

Eur J Med Chem. 2013 Nov;69:191-200. doi: 10.1016/j.ejmech.2013.07.056.

PMID:
24036042
10.

Discovery of Akt kinase inhibitors through structure-based virtual screening and their evaluation as potential anticancer agents.

Chuang CH, Cheng TC, Leu YL, Chuang KH, Tzou SC, Chen CS.

Int J Mol Sci. 2015 Feb 2;16(2):3202-12. doi: 10.3390/ijms16023202.

11.

Deactivation of Akt by a small molecule inhibitor targeting pleckstrin homology domain and facilitating Akt ubiquitination.

Jo H, Lo PK, Li Y, Loison F, Green S, Wang J, Silberstein LE, Ye K, Chen H, Luo HR.

Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6486-91. doi: 10.1073/pnas.1019062108.

12.

Development of 3-phenyl-N-(2-(3-phenylureido)ethyl)-thiophene-2-sulfonamide compounds as inhibitors of antiapoptotic Bcl-2 family proteins.

Yang C, Chen S, Zhou M, Li Y, Li Y, Zhang Z, Liu Z, Ba Q, Li J, Wang H, Yan X, Ma D, Wang R.

ChemMedChem. 2014 Jul;9(7):1436-52. doi: 10.1002/cmdc.201400058.

PMID:
24782462
13.

Discovery of a novel protein kinase B inhibitor by structure-based virtual screening.

Medina-Franco JL, Giulianotti MA, Yu Y, Shen L, Yao L, Singh N.

Bioorg Med Chem Lett. 2009 Aug 15;19(16):4634-8. doi: 10.1016/j.bmcl.2009.06.078.

PMID:
19604696
14.

Discovery and SAR of spirochromane Akt inhibitors.

Kallan NC, Spencer KL, Blake JF, Xu R, Heizer J, Bencsik JR, Mitchell IS, Gloor SL, Martinson M, Risom T, Gross SD, Morales TH, Wu WI, Vigers GP, Brandhuber BJ, Skelton NJ.

Bioorg Med Chem Lett. 2011 Apr 15;21(8):2410-4. doi: 10.1016/j.bmcl.2011.02.073.

PMID:
21392984
15.

Tirucallic acids are novel pleckstrin homology domain-dependent Akt inhibitors inducing apoptosis in prostate cancer cells.

Estrada AC, Syrovets T, Pitterle K, Lunov O, B├╝chele B, Schimana-Pfeifer J, Schmidt T, Morad SA, Simmet T.

Mol Pharmacol. 2010 Mar;77(3):378-87. doi: 10.1124/mol.109.060475.

16.

A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate.

Falasca M, Chiozzotto D, Godage HY, Mazzoletti M, Riley AM, Previdi S, Potter BV, Broggini M, Maffucci T.

Br J Cancer. 2010 Jan 5;102(1):104-14. doi: 10.1038/sj.bjc.6605408.

17.

Synthesis and SAR of indazole-pyridine based protein kinase B/Akt inhibitors.

Woods KW, Fischer JP, Claiborne A, Li T, Thomas SA, Zhu GD, Diebold RB, Liu X, Shi Y, Klinghofer V, Han EK, Guan R, Magnone SR, Johnson EF, Bouska JJ, Olson AM, de Jong R, Oltersdorf T, Luo Y, Rosenberg SH, Giranda VL, Li Q.

Bioorg Med Chem. 2006 Oct 15;14(20):6832-46.

PMID:
16843670
18.
19.

Discovery of pyrrolopyrimidine inhibitors of Akt.

Blake JF, Kallan NC, Xiao D, Xu R, Bencsik JR, Skelton NJ, Spencer KL, Mitchell IS, Woessner RD, Gloor SL, Risom T, Gross SD, Martinson M, Morales TH, Vigers GP, Brandhuber BJ.

Bioorg Med Chem Lett. 2010 Oct 1;20(19):5607-12. doi: 10.1016/j.bmcl.2010.08.053.

PMID:
20810279
20.

Synthesis and biological activity of Akt/PI3K inhibitors.

Redaelli C, Granucci F, De Gioia L, Cipolla L.

Mini Rev Med Chem. 2006 Oct;6(10):1127-36. Review.

PMID:
17073713
Items per page

Supplemental Content

Support Center